Hematology News

University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.

An analysis of individuals in the United States with public insurance showed that those with sickle cell disease died more than 20 years earlier than the average person.

Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with on-demand treatment among men with hemophilia A or B with or without inhibitors, according to results of two randomized phase 3 studies.

Techdow USA announced the FDA approval of its generic enoxaparin sodium for marketing in the U.S.

Massage therapy can benefit young patients with cancer or hematologic conditions, according to retrospective study results.

Fewer than 4% of eligible individuals with sickle cell disease received prescriptions for newer FDA-approved pain medications, according to study results published in Blood Advances.

Survivors of blood or marrow transplants exhibited an increased risk for developing subsequent malignant neoplasms in the gastrointestinal tract, according to results of a cohort study published in JAMA Oncology.

Iron-deficiency among frequent blood donors did not affect the quality of red blood cells for use in transfusions, according to results of a randomized, placebo-controlled study.

Direct oral anticoagulants showed greater efficacy and cost-effectiveness than low-molecular-weight heparin for treatment of cancer-associated thrombosis, according to data published in Annals of Internal Medicine.

The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A.